Suppr超能文献

腹主动脉瘤血管腔内修复术后二次干预的结果

Outcomes of secondary interventions after abdominal aortic aneurysm endovascular repair.

作者信息

Becquemin Jean-Pierre, Kelley Lynne, Zubilewicz Thomasz, Desgranges Pascal, Lapeyre Mathieu, Kobeiter Hischam

机构信息

Departments of Vascular Surgery and Vascular Imaging, Henri Mondor Hospital, University Paris Val de Marne, Creteil, France.

出版信息

J Vasc Surg. 2004 Feb;39(2):298-305. doi: 10.1016/j.jvs.2003.09.043.

Abstract

PURPOSE

We assessed the distribution of secondary interventions after aortic stent grafting (EVAR) performed to treat infrarenal abdominal aortic aneurysm (AAA), and evaluated clinical success and survival in patients who underwent a secondary procedure (group 2) compared with patients who did not undergo a secondary procedure (group 1).

METHODS

Two hundred fifty patients (mean age, 71.3 years) with asymptomatic AAAs (mean aneurysm diameter, 54.5 mm) underwent treatment with commercially available stent grafts. Mean follow-up was 28 months (median, 25 months). Secondary procedures were defined as any additional procedures performed after initial graft placement to treat endoleak, migration, kinking, stenosis, or occlusion. Overall clinical success was defined according to reporting standards of the Society for Vascular Surgery/American Association for Vascular Surgery.

RESULTS

Sixty-eight patients (27%) required 112 secondary procedures, with a mean time from initial graft placement of 18.2 months. Patients who received grafts since removed from the market required more secondary procedures (59%, procedure:patient ratio) compared with patients who received devices still on the market (21%; P =.001). Thirty-six patients (53%) required a single secondary procedure, 24 patients (35%) required two procedures, 5 patients (10%) required three procedures, 2 patients (3%) required four procedures, and 1 patient required five secondary procedures. Ninety-eight procedures (87%) were performed with endovascular methods, including placement of 42 additional covered stent grafts (36 iliac, 6 aortic), with a success rate of 85%; 35 embolization procedures (21 lumbar, 9 internal iliac artery, 5 mesenteric), with only 23 (65%) successful; 14 angioplasty procedures, with 85% successful; 4 thrombolysis procedures, 2 of them successful (50%); and 3 successfully placed new endografts within a previous endovascular graft. Surgical secondary operations included nine femorofemoral bypass procedures and three femoral thromboendarterectomies, all of which remain patent; one cerclage of an external iliac limb; and one laparoscopic repair of a type II endoleak, which was successful. Overall clinical success rate for EVAR was 84% (211 of 250) in this series. Clinical success rate in groups 1 and 2 was 91% (166 of 182) versus 66% (45 of 68; P =.001) if all endoleaks on the most recent computed tomography scans are taken into account, and 94% (171 of 182) versus 76% (52 of 68; P =.001) if type II endoleak without aneurysm growth is not considered failure. The survival rate and rupture-free survival in groups 1 and 2 were, respectively, 97.7% +/- 1.0% and 98.5% +/- 1.4% at 1 month, 95.9% +/- 1.5% and 96.9% +/- 2.1% at 6 months, 94.4% +/- 2.0% and 93.2% +/- 3.4% at 1 year, and 80.8% +/- 5.2% and 88.5% +/- 5.0% at 3 years (P =.273, log-rank test).

CONCLUSION

With close follow-up and a significant number of secondary operations, this 8-year experience has not included any aneurysm ruptures to date. Secondary operations did not lead to increased mortality, but were associated with more surgical conversions and with a higher clinical failure rate.

摘要

目的

我们评估了为治疗肾下腹主动脉瘤(AAA)而进行主动脉支架植入术(EVAR)后二次干预的分布情况,并评估了接受二次手术的患者(第2组)与未接受二次手术的患者(第1组)的临床成功率和生存率。

方法

250例无症状AAA患者(平均年龄71.3岁,平均动脉瘤直径54.5mm)接受了商用支架植入治疗。平均随访时间为28个月(中位数为25个月)。二次手术定义为在初次植入移植物后为治疗内漏、移位、扭结、狭窄或闭塞而进行的任何额外手术。总体临床成功根据血管外科学会/美国血管外科学会的报告标准定义。

结果

68例患者(27%)需要进行112次二次手术,从初次植入移植物到进行二次手术的平均时间为18.2个月。与接受仍在市场上的器械的患者相比,接受已退市移植物的患者需要更多的二次手术(59%,手术与患者比例)(21%;P=0.001)。36例患者(53%)需要进行单次二次手术,24例患者(35%)需要进行两次手术,5例患者(10%)需要进行三次手术,2例患者(3%)需要进行四次手术,1例患者需要进行五次二次手术。98次手术(87%)采用血管内方法进行,包括植入42个额外的覆膜支架移植物(36个髂动脉,6个主动脉),成功率为85%;35次栓塞手术(21次腰动脉,9次髂内动脉,5次肠系膜动脉),仅23次(65%)成功;14次血管成形术,成功率为85%;4次溶栓手术,其中2次成功(50%);3次成功在先前的血管内移植物内植入新的腔内移植物。外科二次手术包括9次股股旁路手术和3次股动脉血栓内膜切除术,所有这些手术均保持通畅;1次髂外肢体环扎术;以及1次成功的II型内漏腹腔镜修复术。本系列中EVAR的总体临床成功率为84%(250例中的211例)。如果考虑最近计算机断层扫描上的所有内漏,第1组和第2组的临床成功率分别为91%(182例中的166例)和66%(68例中的45例;P=0.001),如果不将无动脉瘤生长的II型内漏视为失败,则分别为94%(182例中的171例)和76%(68例中的52例;P=0.001)。第1组和第2组在1个月时的生存率和无破裂生存率分别为97.7%±1.0%和98.5%±1.4%,6个月时为95.9%±1.5%和96.9%±2.1%,1年时为94.4%±2.0%和93.2%±3.4%,3年时为80.8%±5.2%和88.5%±5.0%(P=0.273,对数秩检验)。

结论

通过密切随访和大量二次手术,这8年的经验至今未出现任何动脉瘤破裂情况。二次手术并未导致死亡率增加,但与更多的手术转换和更高的临床失败率相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验